In a study of patients with cutaneous sarcoidosis, ECG abnormalities identified all cases of cardiac involvement, demonstrating 100% sensitivity and 100% negative predictive value. Researchers ...

CHICAGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) expresses both solidarity and resolve as aTyr Pharma announced that its Phase 3 trial of efzofitimod in ...

Her case is unusual as the disease, which typically affects the lungs, has impacted 15 other parts of her body. Despite having health insurance, she has accumulated $4,500 in out-of-pocket medical ...

(RTTNews) - aTyr Pharma, Inc. (ATYR) Monday said that its Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, a major form of interstitial lung disease, failed to meet its ...

Biotech firm aTyr Pharma Inc. (NASDAQ:ATYR) plummeted over 81% at last check on Monday, with a session volume of 34.7 million compared to the average volume of 4.83 million as per data from Benzinga ...

SAN DIEGO - aTyr Pharma, Inc. (NASDAQ:ATYR), whose stock has surged over 217% in the past year according to InvestingPro data, announced Monday that its Phase 3 EFZO-FIT study of efzofitimod in ...

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters ...

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

Pulmonary sarcoidosis is a condition that causes tiny groups of immune cells to clump in your lungs. These groups of cells form swollen, inflamed lumps called granulomas. Granulomas can make it hard ...

Cardiovascular magnetic resonance (CMR) imaging may help physicians make decisions about which patients with suspected cardiac sarcoidosis require an implantable cardioverter-defibrillator (ICD) to ...

New-onset osteopenia/osteoporosis among long-term survivors of breast cancer: Role of hormone therapies and metabolic risk factors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I ...